Recent Advances in Celiac Disease.
Recent diagnostic advances have demonstrated that celiac disease is relatively common although most patients have less florid symptoms than previously recognised. The mucosal lesion of this autoimmune disorder depends on both adaptive and innate immune responses. The characteristic antibodies to tissue transglutaminase-2 (tTG-2) and deamidated gliadin peptides may be produced in persons possessing the relevant HLA-DQ genotypes if intact gliadin peptides can penetrate the epithelial barrier to reach antigen presenting cells. Progression from celiac autoimmunity to overt disease may depend on innate immune mechanisms, not HLA-restricted, where IL-15 is generated within the epithelial compartment. A specific innate immune response previously thought restricted to invertebrates, the encapsulation reaction, may contribute to mucosal volume expansion through recruitment of syndecan-expressing leukocytes and stimulated matrix production. It is notable that tissue transglutaminase is critical in this reaction in insects, and that the very few insects that can predate wheat, possess specific salivary or intestinal enzymes that degrade gluten. Animal models in HLA-DQ transgenic mice suggest that the microbial flora of the intestine may play a role in host responses and modulate the evolution of the disease. This suggests that therapeutic modulation of the microbiome may contribute to management of celiac disease. In developing world countries, there is a potential difficulty in histological diagnosis because of the widespread incidence of environmental enteropathy amongst apparently healthy children. Thus, recognition of local patterns of enteropathy will be important for histopathologists, and high titre tTG-2 autoantibody titres may hold considerable diagnostic significance.
Emeritus Professor, Warwick University, Coventry, UK. S.Murch@warwick.ac.uk.|Consultant Paediatric Gastroenterologist, University Hospital Coventry and Warwickshire, Coventry, UK. S.Murch@warwick.ac.uk.
Simon
S
Murch
D000818:Animals; D002446:Celiac Disease / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy; D005903:Gliadin; D005983:Glutens; D006683:HLA-DQ Antigens; D006801:Humans; D007422:Intestines; D051379:Mice; D008822:Mice, Transgenic; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases
D006683:HLA-DQ Antigens; C000717608:TGM2 protein, human; D005983:Glutens; D005903:Gliadin; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases
Celiac disease; HLA-DQ; Syndecan-1; Tissue transglutaminase